Visceral leishmaniasis and COVID-19 coinfection – A case report
Antonis Pikoulas,
Evangelia-Theophano Piperaki,
Gregory Spanakos,
Anastasios Kallianos,
Despoina Mparmparousi,
Gianna Rentziou,
Georgia Trakada
Affiliations
Antonis Pikoulas
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Department of Medicine, University of Crete and Foundation for Research and Technology, Heraklion, Greece
Evangelia-Theophano Piperaki
Department of Microbiology, Medical School, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Gregory Spanakos
National Public Health Organization, Vari, Greece
Anastasios Kallianos
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Despoina Mparmparousi
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Gianna Rentziou
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Georgia Trakada
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece; Correspondence to: Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Alexandra General Hospital, 80 Vas. Sofias Avenue, 11528 Athens, Greece.
As the COVID-19 pandemic spreads across the globe, it will undoubtedly cross paths with long endemic infectious diseases in different areas. Interactions between SARS-CoV2 and well-known pathogens will likely give rise to unfamiliar clinical presentations, depending on complex and as yet unknown immunological interactions. We present a case of coinfection with COVI19 and visceral leishmaniasis and discuss recent reports regarding coexistence of SARS-CoV2 and Leishmania spp. to date.
